Please ensure Javascript is enabled for purposes of website accessibility

Better Coronavirus Stock: Sorrento Therapeutics vs. Regeneron

By Keith Speights – Jun 16, 2020 at 6:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a battle of big vs. little with these two COVID-19-focused biotechs.

In case you haven't noticed, antibody therapies are all the rage when it comes to developing potential treatments for COVID-19. Two companies in the thick of the race with experimental novel-coronavirus antibody therapies are Sorrento Therapeutics (SRNE -2.58%) and Regeneron Pharmaceuticals (REGN -1.61%).

Both biotech stocks have been big winners so far in 2020. Sorrento's shares have skyrocketed more than 50%, while Regeneron is up more than 40%. Which of these coronavirus-focused stocks is the better pick for long-term investors?

Gloved hand separating fallen wooden dominoes spelling out COVID19 from a set of standing dominoes

Image source: Getty Images.

The case for Sorrento Therapeutics

Two potential COVID-19 cures waiting in the wings? That's how Sorrento Therapeutics CEO Henry Ji might put it. After Sorrento first announced in May that it had identified an antibody that could completely neutralize SARS-CoV-2, Ji went on TV saying that his company could be on track to have a cure for COVID-19.

Earlier this month, Sorrento reported that another antibody, discovered in March, also demonstrated the ability to completely inhibit the novel coronavirus. These two antibodies that could potentially serve as antidotes to COVID-19 aren't the only coronavirus programs that Sorrento is working on, though.

The company recently submitted an application to the Food and Drug Administration for Emergency Use Authorization for its COVI-TRACK in vitro diagnostic test for detecting COVID-19 antibodies. It's collaborating with Mount Sinai Health System in New York City to develop COVID-19 antibody cocktail therapies. Sorrento also launched an effort to develop a COVID-19 vaccine.

None of Sorrento's COVID-19 antibody therapy or vaccine candidates have advanced beyond preclinical testing yet. However, the biotech's pipeline includes five clinical-stage programs that aren't related to the coronavirus. Its lead candidate, resiniferatoxin (RTX), is being evaluated in phase 2 clinical studies for treating the pain of terminal cancer and pain associated with osteoarthritis. Sorrento also has three cancer immunotherapies in early-stage development.

The biggest argument for buying Sorrento shares is that pretty much any success would likely be a major catalyst. Sorrento's market cap is currently around $1 billion. All it would take for the biotech to take off would be some positive news from planned clinical testing of its COVID-19 programs.

The case for Regeneron

Regeneron is mounting a fight against COVID-19 on two fronts. The company and its partner Sanofi are evaluating rheumatoid arthritis drug Kevzara in a phase 2/3 study for treating patients with respiratory illness caused by COVID-19. After a review by the study's Independent Data Monitoring Committee in late April, the trial refocused only on more critical patients.

Last week, Regeneron began a phase 1 clinical study evaluating an antibody cocktail for both preventing and treating COVID-19. The biotech thinks that this antibody cocktail could be available much sooner than a vaccine, and treat patients already diagnosed with the novel coronavirus disease. It also anticipates that the cocktail could be helpful for elderly and immunocompromised patients who don't respond well to COVID-19 vaccines.

Unlike Sorrento, Regeneron doesn't need its COVID-19 programs to go well to be successful. The company raked in $1.83 billion in sales in the first quarter of 2020, up 33% year over year. It's already quite profitable, with earnings soaring 36% year over year in Q1 to $625 million.

Regeneron claims multiple big winners in its lineup. Sales continue to climb for blockbuster eye-disease drug Eylea. Momentum is picking up strongly for immunology drug Dupixent. Recent positive clinical results for Libtayo could lead to expanded indications for the immunotherapy, as a first-line treatment for non-small cell lung cancer and as a second-line treatment for advanced basal cell carcinoma.

Meanwhile, Regeneron's pipeline is loaded with candidates that could pave the way for future growth. The company has eight late-stage programs, 12 phase 2 programs, and 10 phase 1 programs (including its COVID-19 antibody cocktail).

The better coronavirus stock

You've probably heard the old expression that "a bird in the hand is worth two in the bush." I think that adage applies to the choice between Sorrento and Regeneron.

Sorrento has some intriguing candidates, but they're all early in development. Regeneron has several successful drugs already on the market, plus a deep pipeline. Sorrento could potentially become a big winner; Regeneron already is a big winner. And with its antibody cocktail already in clinical testing, it has a big head start over Sorrento on the COVID-19 front.

Regeneron is the better coronavirus stock. It's the better stock, period.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$686.10 (-1.61%) $-11.23
Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
$1.51 (-2.58%) $0.04
Sanofi Stock Quote
$37.25 (-3.00%) $-1.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.